It's been shown that an overactive immune response increases the chance of depression through corticotropin releasing factor . The main mechanisms seem to be increased TNF alpha, increased IL-6 and most interestingly beta arrestin-1 downregulation.

Beta arrestin-1 binds to CCR5 and lowers binding affinity of other chemokines (cytokines). Beta arrestin-1 can lower tumor growth, modulate insulin production, lower inflammation and a host of other protective mechanisms. It makes me wonder if leronlimab's binding sites on CCR5 mimic those of beta arrestin-1.

There are genetic anomalies that result in lowered production of beta arrestin-1. It might be that those anomalies might contribute to the immune overreaction seen in COVID-19, increased risk of cancer and diabetes and other diseases.